65,437 trials
Ovarian Cancer · Breast Cancer · Folic Acid Deficiency
Primary: Number of Participants Who Have Developed Folate Deficiency (Serum Folate Level < 7 ng/ml) on Olaparib — 2; 6 Participants
Fathers · Mothers
Primary: Primary Outcome Measure 1: Retention Rates Among Participants — 20; 13; 76; 78 Participants
Plasma Cell Myeloma
Primary: Treatment Satisfaction Will be Measured Using the SWT Score From the Cancer Treatment Satisfaction Questionnaire (CTSQ) - Cycle 1 — 87.2 scores on a scale (0-100)
Parkinson Disease
Primary: Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score — -1.2; -10.3 score on a…
Youth Engagement
Primary: Crow Knowledge — 8; 2 Participants
Alopecia Areata
Primary: Number of Participants With Adverse Events as a Measure of Safety — 308; 224 Participants
Full Thickness Skin Defects · Ulcer
Primary: Percentage Change in Wound Area — 23.73; 15.21; 34.47; 22.52 percentage change
Lung Cancer
Primary: Reaching Screening Eligible Individuals Via Social Media - Reach — 1048191 participants
COVID-19 · Vaccine-Preventable Diseases · SARS CoV 2 Infection
Primary: Number of Symptomatic SARS-CoV-2 Infections Between Randomized, Study-vaccinated Participants and the Comparator Group — 48; 94 Participants
Necrotizing Enterocolitis
Primary: Days to Full Enteral Feeds: Extended Rule Out Group — 10.1; 4.9 days
Physical Inactivity
Primary: Total Minutes of Time Spent in Moderate to Vigorous Physical Activity (MVPA) — 548; 512; 354; 737 minutes of MVPA per week
Diabetic Foot Ulcer (DFU)
Primary: Percentage Change in Wound Area — 81.5; 64.2 percentage change
Hoarding Disorder · Hoarding · Clutter
Primary: Number of Patients Who Met and Exceeded Response Criteria of the Saving Inventory-Revised (SI-R) — 9; 13 Participants
Primary Progressive Aphasia · Behavioral Variant of Frontotemporal Dementia · Frontotemporal Dementia, Behavioral Variant
Primary: Proportion of PPA Subjects That Showed Elevated Tau PET Binding Compared to Normal Controls — 3; 0; 17; 0 Participants
Pancreatic Adenocarcinoma
Primary: Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1…